EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma

Simon Krols iD, Muhammad Rishfi, Fien Martens, Anouk Van Hauwermeiren, Ellen Sanders, Pieter-Jan De Sutter, An Vermeulen, Kaat De Wever, Sarah-Lee Bekaert, M Emmy M Dolman, Gabor Tax, Alvin Kamili und 5 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Simon Krols und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medicinal Chemistry, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Gh…. Hauptthemen laut MEDLINE: Aurora Kinase A, Neuroblastoma, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Stichting Villa Joep, Kom op tegen Kanker.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aurora kinase A (AURKA) is an established oncogenic factor and therapeutic target in neuroblastoma due to its roles in mitosis and stability of the MYCN protein. We previously identified SK2188 as a highly potent, selective, and fast-acting AURKA degrader capable of inducing MYCN destabilization. However, SK2188 showed low systemic exposure and rapid clearance in mice, necessitating further chemical optimization. Here, we describe our structure–activity optimization efforts involving linker rigidification and incorporation of alternative cereblon- and AURKA-recruiting ligands, leading to two optimized PROTACs, SK4454 and SK5527. Both compounds retained rapid and selective AURKA degradation with improved pharmacokinetic properties. Importantly, single intravenous administration of either degrader efficiently reduced AURKA levels in vivo in a neuroblastoma xenograft mouse model. Moreover, MDR1-mediated PROTAC efflux was identified as a key intrinsic mechanism limiting in vitro potency. These results establish SK4454 and SK5527 as advanced AURKA degraders with improved pharmacokinetic properties, warranting further preclinical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aurora Kinase ANeuroblastomaAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimalsMiceStructure-Activity RelationshipCell Line, TumorXenograft Model Antitumor AssaysUbiquitin-Protein LigasesProteolysisProteolysis Targeting Chimera

Substanzen

Aurora Kinase AAURKA protein, humanAntineoplastic AgentsProtein Kinase InhibitorsUbiquitin-Protein LigasesProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Laboratory of Medicinal Chemistry, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
  • Cancer Research Institute Ghent, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
  • Pediatric Precision Oncology Lab, Department of Biomolecular Medicine, Faculty of Medicine & Health Sciences, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium.
  • Laboratory of Medical Biochemistry and Clinical Analysis, Department of Bioanalysis, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, Sydney, NSW 2052, Australia.
  • School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Kensington, Sydney, NSW 2052, Australia.

ORCID-Profile: Simon Krols, Lisa Depestel, Kaat Durinck, Serge Van Calenbergh

Förderung

  • Fonds Wetenschappelijk Onderzoek
  • Stichting Villa Joep
  • Kom op tegen Kanker

Zitieren

APA

Krols, S., Rishfi, M., Martens, F., Van Hauwermeiren, A., Sanders, E., De Sutter, P. J., Vermeulen, A., De Wever, K., Bekaert, S. L., Dolman, M. E. M., Tax, G., Kamili, A., Fletcher, J. I., Depestel, L., De Wilde, B., Durinck, K., & Van Calenbergh, S. (2025). Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01271

Vancouver

Krols S, Rishfi M, Martens F, Van Hauwermeiren A, Sanders E, De Sutter PJ, et al. Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01271

BibTeX
@article{Krols2025,
  author = {Krols, Simon and Rishfi, Muhammad and Martens, Fien and Van Hauwermeiren, Anouk and Sanders, Ellen and De Sutter, Pieter-Jan and Vermeulen, An and De Wever, Kaat and Bekaert, Sarah-Lee and Dolman, M Emmy M and Tax, Gabor and Kamili, Alvin and Fletcher, Jamie I and Depestel, Lisa and De Wilde, Bram and Durinck, Kaat and Van Calenbergh, Serge},
  title = {Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01271}
}
Kostenlos starten →